British woman first to receive new cancer treatment

British woman Tracy Tomlinson, 58 years old, successfully received the first experimental allogeneic treatment called "ZI-MA4-1." The treatment aims to evaluate its effectiveness and safety in treating advanced types of cancer, including ovarian and lung cancers. It is based on combining immune cells obtained from donors, utilizing genetic engineering techniques to modify T-cell receptors to target the "Mage-A4" protein, which is present in many tumors. This approach enables the immune system to attack cancer cells more precisely. This treatment represents an important step forward in developing more effective therapeutic options for patients who have exhausted most of their existing choices. It also has the potential to produce hundreds of doses from a single manufacturing batch, reducing costs and increasing treatment accessibility. Tracy’s trial marks a milestone in cellular therapy applications and comes as part of ongoing efforts to open new horizons in the treatment of advanced and difficult-to-treat cancers. Notably, the survival rates for ovarian cancer remain low, with only about 15% of patients living five years or more.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل